This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Eli Lilly and Company.
Reference
Schweikert B, et al. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open : 13 Aug 2020. Available from: URL: http://dx.doi.org/10.1136/bmjopen-2019-032552
Rights and permissions
About this article
Cite this article
Ixekizumab in psoriatic arthritis: more QALYs, lower cost in Spain. PharmacoEcon Outcomes News 861, 24 (2020). https://doi.org/10.1007/s40274-020-7106-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7106-9